Astellas Broadens Commitment to Clinical Trial Data Transparency
Astellas Pharma Inc. (Tokyo: 4503, "Astellas") announced today that the company will now make trial data available through www.clinicalstudydatarequest.com,
Astellas Pharma announced that the company will now make trial data available through www.clinicalstudydatarequest.com, an independent Web site that enables researchers to request and access clinical trial data after approval of a research proposal by an independent review panel. This site was developed to enable researchers to request data from clinical studies and perform further research that could help advance medical science or improve patient care. In addition, Astellas also recently revised and expanded its Global Policy on Clinical Trial Data Disclosure, which details the company's principles regarding registration of clinical trials, posting and publication of trial results and scientific community access to trial data. The policy is available at www.astellas.com/en/corporate/disclosure/clinicalstudies.html.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
